August 2021

25-Year Survival Data on Tamoxifen in ER+/ERBB2-Negative BC
The utility of breast cancer (BC) markers (i.e., tumor size, tumor grade, estrogen and progesterone receptor status, Ki-67 expression) is known for up to about 10 years following the initial diagnosis of BC, but their benefit beyond this point remains unclear. Further, although endocrine therapy is typically recommended, about one-half of women do not benefit from it, which contributes to death secondary to distant metastases in one of every four BC patients. Read more.


Celecoxib Safe, but Not Effective, for Breast Cancer
The rationale supporting nonsteroidal anti-inflammatory agents (NSAIAs) as adjuvant cancer therapy is based on evidence that chronic immune activation and associated inflammation may play a role in cancer progression. Proposed mechanisms ascribed to NSAIAs' potential benefit include inhibition of procarcinogenic activation and formation, tumor-cell invasion, and metastasis. Cyclooxygenase-2 is expressed in breast cancer, leading to the hypothesis that celecoxib may be beneficial. Read more.

Racial and Ethnic Differences in Treatment and Survival of Women With TNBC
Triple-negative breast cancer (TNBC) accounts for 10% to 12% of all invasive BC cases in the United States and is associated with a worse prognosis than other types of BC. It is also twice as common among African American women. However little is known about the racial, ethnic, and socioeconomic factors that may be contributing to this disparity. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App